Citius Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) covers the event date of June 30, 2016, for Citius Pharmaceuticals, Inc., a Nevada corporation. The filing addresses the discontinuation of the Company's FDA-approved weight loss product, Suprenza.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or debt figures for the period. However, it notes the following financial implications:
- Revenue: The Company has not previously received royalties from Suprenza.
- Expenses: Discontinuation will eliminate ongoing regulatory expenses associated with annual FDA fees.
- Liabilities: Parties will have no further payment obligations under the licensing agreement, except for payments accrued prior to June 30, 2016.
Material Changes
On June 30, 2016, the Company notified the FDA of the discontinuation of Suprenza. Consequently, the Company terminated the exclusive licensing agreement with Prenzamax LLC and Akrimax Pharmaceuticals LLC, effective immediately. All shipments of Suprenza were required to cease as of this date.
Outlook, Risks, and Unusual Items
Management Commentary: The Company issued a press release on July 1, 2016, confirming the discontinuation. The move ends the commercialization responsibilities of Prenzamax and Akrimax.
Related Party Transaction: The filing discloses a related party relationship. Leonard Mazur, the Executive Chairman and Secretary of Citius Pharmaceuticals, is also the co-founder and Vice Chairman of Akrimax. Prenzamax is an affiliate of Akrimax formed specifically to manage the license.
Risks/Contingencies: The filing does not explicitly list new risks, though the discontinuation of a primary product line represents a significant operational change.
Investor Verification Checklist
- Verify the status of any accrued but unpaid royalties or obligations under the terminated agreement with Prenzamax/Akrimax.
- Confirm the exact amount of annual FDA regulatory fees that will be eliminated.
- Review the July 1, 2016 press release (Exhibit 99.1) for additional details on the strategic rationale.
- Assess the impact of losing the Suprenza product line on the Company's future revenue pipeline and liquidity.